{
  "data": {
    "id": "stat_AMY20EM2RNW8Q9RJFE4WN91N7E",
    "url": "https://statorigin.org/stat/stat_AMY20EM2RNW8Q9RJFE4WN91N7E",
    "indicator": {
      "slug": "ctgov-glp1-active-trials",
      "name": "Active GLP-1, incretin multi-agonist and amylin trials",
      "definition": "Count of interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) whose overall status is recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation."
    },
    "industry": [
      {
        "slug": "pharmaceuticals",
        "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
        "isic": "C21",
        "is_primary": true
      }
    ],
    "region": {
      "code": "GLOBAL",
      "name": "Global",
      "type": "world"
    },
    "period": {
      "start": "2026-09-27",
      "end": "2026-09-27",
      "type": "point"
    },
    "value": 600,
    "value_text": "600 studies",
    "unit": "count",
    "currency": null,
    "scale": "1",
    "value_type": "actual",
    "source": {
      "org": "ClinicalTrials.gov (U.S. National Library of Medicine)",
      "org_short_name": "ClinicalTrials.gov",
      "org_url": "https://clinicaltrials.gov",
      "org_tier": 1,
      "document_title": "ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27",
      "document_url": "https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId",
      "document_type": "dataset",
      "locator": "totalCount field of the API response. Query: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27.",
      "quote": "{\"totalCount\":600,\"studies\":[",
      "published_date": null,
      "accessed_at": "2026-09-27",
      "license": "public-domain",
      "url_status": "ok",
      "self_reported": false
    },
    "verification": "verified",
    "verified_by": "pipeline:ctgov-api-totalcount-verified",
    "verified_at": "2026-09-27T12:00:00.000Z",
    "confidence": 0.95,
    "is_secondhand": false,
    "supersedes": "stat_H2J37R3RP64F5N7DM8EF25RM6S",
    "superseded_by": null,
    "is_current": true,
    "citation": {
      "apa": "ClinicalTrials.gov (U.S. National Library of Medicine). (2026). ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27. Retrieved September 27, 2026, from https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide%20OR%20tirzepatide%20OR%20retatrutide%20OR%20orforglipron%20OR%20survodutide%20OR%20cagrilintide%20OR%20CagriSema%20OR%20mazdutide%20OR%20liraglutide%20OR%20dulaglutide%20OR%20exenatide%20OR%20ecnoglutide%20OR%20danuglipron%20OR%20pemvidutide%20OR%20amycretin%20OR%20efinopegdutide%20OR%20MariTide%20OR%20maridebart%20OR%20petrelintide%20OR%20%22GLP-1%20receptor%20agonist%22%20OR%20LY3437943%20OR%20LY3502970%20OR%20%22BI%20456906%22%20OR%20LY3298176%20OR%20IBI362%20OR%20%22AMG%20133%22%20OR%20%22NNC0487-0111%22&filter.advanced=AREA%5BStudyType%5DINTERVENTIONAL&filter.overallStatus=RECRUITING%2CNOT_YET_RECRUITING%2CACTIVE_NOT_RECRUITING%2CENROLLING_BY_INVITATION&countTotal=true&pageSize=1&fields=NCTId. Via StatOrigin, https://statorigin.org/stat/stat_AMY20EM2RNW8Q9RJFE4WN91N7E",
      "bibtex": "@misc{clinicaltrialsgo2026ctgovn91n7e,\n  author       = {{ClinicalTrials.gov (U.S. National Library of Medicine)}},\n  title        = {ClinicalTrials.gov study count: Interventional studies whose interventions name a GLP-1 receptor agonist, a GLP-1-based multi-agonist or an amylin analogue developed for obesity (semaglutide, tirzepatide, retatrutide, orforglipron, survodutide, CagriSema, cagrilintide, petrelintide, mazdutide, MariTide, amycretin and others, including development codes) with overall status recruiting, not yet recruiting, active (not recruiting) or enrolling by invitation, on 2026-09-27},\n  year         = {2026},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_AMY20EM2RNW8Q9RJFE4WN91N7E},\n  note         = {Original source: https://clinicaltrials.gov/api/v2/studies?query.intr=semaglutide\\%20OR\\%20tirzepatide\\%20OR\\%20retatrutide\\%20OR\\%20orforglipron\\%20OR\\%20survodutide\\%20OR\\%20cagrilintide\\%20OR\\%20CagriSema\\%20OR\\%20mazdutide\\%20OR\\%20liraglutide\\%20OR\\%20dulaglutide\\%20OR\\%20exenatide\\%20OR\\%20ecnoglutide\\%20OR\\%20danuglipron\\%20OR\\%20pemvidutide\\%20OR\\%20amycretin\\%20OR\\%20efinopegdutide\\%20OR\\%20MariTide\\%20OR\\%20maridebart\\%20OR\\%20petrelintide\\%20OR\\%20\\%22GLP-1\\%20receptor\\%20agonist\\%22\\%20OR\\%20LY3437943\\%20OR\\%20LY3502970\\%20OR\\%20\\%22BI\\%20456906\\%22\\%20OR\\%20LY3298176\\%20OR\\%20IBI362\\%20OR\\%20\\%22AMG\\%20133\\%22\\%20OR\\%20\\%22NNC0487-0111\\%22\\&filter.advanced=AREA\\%5BStudyType\\%5DINTERVENTIONAL\\&filter.overallStatus=RECRUITING\\%2CNOT\\_YET\\_RECRUITING\\%2CACTIVE\\_NOT\\_RECRUITING\\%2CENROLLING\\_BY\\_INVITATION\\&countTotal=true\\&pageSize=1\\&fields=NCTId. Accessed September 27, 2026.}\n}"
    },
    "updated_at": "2026-09-27T01:11:36.992Z",
    "contested_by": [],
    "related": []
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}